2-{[(3-chlorophenyl)methyl]oxy}benzoic acid | 121697-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{[(3-chlorophenyl)methyl]oxy}benzoic acid
• 英文别名: 2-[(3-Chlorobenzyl)oxy]benzoic acid；2-[(3-chlorophenyl)methoxy]benzoic acid
• CAS: 121697-55-0
• 化学式: C₁₄H₁₁ClO₃
• mdl: MFCD09714441
• 分子量: 262.693
• InChiKey: ZZLXYZLVZBXJBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-{[(3-chlorophenyl)methyl]oxy}benzoic acid 、 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-methylbenzenesulfonate 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以76.27%的产率得到2-(2-methyl-5-nitro-1H-imidazol-1-yl)-ethyl 2-((3-chlorobenzyl)oxy)benzoate
  参考文献：
  名称：

  Design, synthesis and molecular docking of salicylic acid derivatives containing metronidazole as a new class of antimicrobial agents

  摘要：

  A series of novel salicylic acid derivatives containing metronidazole as Staphylococcus aureus Tyrosyl-tRNA synthetase (TyrRS) inhibitors have been synthesized and evaluated their biology activities as potential antibacterial agents. Among these compounds, compound 5r exhibited the most potent antibacterial activity against Gram-positive (S. aureus ATCC 6538 and Bacillus subtilis ATCC 6633) and Gram-negative (Escherichia coli ATCC 35218 and Pseudomonas aeruginosa ATCC 13525) with MICs of 0.39-1.57 mu g/mL and showed the most potent S. aureus Tyrosyl-tRNA synthetase inhibitory with 2.3 mu M. Docking simulation was performed to insert compound 5r into the crystal structure of S. aureus Tyrosyl-tRNA synthetase active site to determine the probable binding model. These results suggested that compound 5r may be a promising antibacterial agent. (c) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.07.075
• 作为产物：
  描述：

  methyl 2-{[(3-chlorophenyl)methyl]oxy}benzoate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 2-{[(3-chlorophenyl)methyl]oxy}benzoic acid
  参考文献：
  名称：

  Design, synthesis and molecular docking of salicylic acid derivatives containing metronidazole as a new class of antimicrobial agents

  摘要：

  A series of novel salicylic acid derivatives containing metronidazole as Staphylococcus aureus Tyrosyl-tRNA synthetase (TyrRS) inhibitors have been synthesized and evaluated their biology activities as potential antibacterial agents. Among these compounds, compound 5r exhibited the most potent antibacterial activity against Gram-positive (S. aureus ATCC 6538 and Bacillus subtilis ATCC 6633) and Gram-negative (Escherichia coli ATCC 35218 and Pseudomonas aeruginosa ATCC 13525) with MICs of 0.39-1.57 mu g/mL and showed the most potent S. aureus Tyrosyl-tRNA synthetase inhibitory with 2.3 mu M. Docking simulation was performed to insert compound 5r into the crystal structure of S. aureus Tyrosyl-tRNA synthetase active site to determine the probable binding model. These results suggested that compound 5r may be a promising antibacterial agent. (c) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.07.075

文献信息

• [EN] NOVEL EP4 RECEPTOR AGONIST COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS AGONISTES DES RÉCEPTEURS EP4
  申请人：GLAXO GROUP LTD

  公开号：WO2009147165A1

  公开（公告）日：2009-12-10

  A compound selected from the group consisting of: (3-chloro-4-[(5-chloro-2-[(2- chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; 4-[(5-chloro-2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; 3-chloro-4-[(5-chloro-2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (3-chloro-4-[(5-chloro-2-[(3- chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; 4-[(2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (4-[(5-chloro-2-[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}-2- fluorophenyl)acetic acid; 3-chloro-4-[(2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (3-chloro-4-[(2-[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; 4-[(2-chloro-6-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (4-[(2-chloro-6-[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; 4-[(5-chloro-2-[(phenylmethyl)amino]phenyl}carbonyl)amino]phenyl}acetic acid; (4-[(5-chloro-2-[(3-chlorophenyl)methyl]amino}phenyl)carbonyl]amino}phenyl)acetic acid; and (4-[(5-chloro-2-[(2-chlorophenyl)methyl]amino}phenyl)carbonyl]amino}phenyl)acetic acid, or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  从以下组中选择的化合物：（3-氯-4-[(5-氯-2-[(2-氯苯基)甲氧基}苯基)羰基]氨基}苯基）乙酸；4-[(5-氯-2-[(苯甲基)氧基]苯基}羰基)氨基]苯基}乙酸；3-氯-4-[(5-氯-2-[(苯甲基)氧基]苯基}羰基)氨基]苯基}乙酸；（3-氯-4-[(5-氯-2-[(3-氯苯基)甲氧基}苯基)羰基]氨基}苯基）乙酸；4-[(2-[(苯甲基)氧基]苯基}羰基)氨基]苯基}乙酸；（4-[(5-氯-2-[(3-氯苯基)甲氧基}苯基)羰基]氨基}-2-氟苯基）乙酸；3-氯-4-[(2-[(苯甲基)氧基]苯基}羰基)氨基]苯基}乙酸；（3-氯-4-[(2-[(3-氯苯基)甲氧基}苯基)羰基]氨基}苯基）乙酸；4-[(2-氯-6-[(苯甲基)氧基]苯基}羰基)氨基]苯基}乙酸；（4-[(2-氯-6-[(3-氯苯基)甲氧基}苯基)羰基]氨基}苯基）乙酸；4-[(5-氯-2-[(苯甲基)氨基]苯基}羰基)氨基]苯基}乙酸；（4-[(5-氯-2-[(3-氯苯基)甲氨基}苯基)羰基]氨基}苯基）乙酸；和（4-[(5-氯-2-[(2-氯苯基)甲氨基}苯基)羰基]氨基}苯基）乙酸，或其药学上可接受的盐，包含这些化合物的药物组合物以及这些化合物在医学上的用途。
• PHARMACEUTICAL COMPOSITION AND METHOD
  申请人：Slade Rachel M.

  公开号：US20090155903A1

  公开（公告）日：2009-06-18

  The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ 42 -related diseases and disorders.

  该发明提供了化合物、制药组合物和方法，用于治疗和预防神经退行性疾病和其他与Aβ42相关的疾病和障碍。
• PIPERAZINE DERIVATIVES AS ALPHA 1A-ADRENERGIC RECEPTOR ANTAGONISTS
  申请人：RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.

  公开号：EP0711288A1

  公开（公告）日：1996-05-15
• JPH09500883A
  申请人：——

  公开号：JPH09500883A

  公开（公告）日：1997-01-28
• [EN] PIPERAZINE DERIVATIVES AS alpha 1A-ADRENERGIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PIPERAZINE UTILISES COMME ANTAGONISTES DES RECEPTEURS alpha 1A-ADRENERGIQUES
  申请人：——

  公开号：WO1995004049A1

  公开（公告）日：1995-02-09

  [EN] There are disclosed compounds of general formula (I). Y is a linking group, chosen from a wide range, but including -COO-, -CH2COO-, -CONH-, -CON(CH3)-, -CH2CONH-, -SO2NH-, -SO2N(CH3)- and -PO(OC2H5)NH-. W is an alkylene chain. A is a substituted phenyl group or a benzofuran or benzodioxan group. R and R1 may have many values, but R is preferably a bulky group. These compounds and their prodrugs, enantiomers, diastereoisomers, N-oxides and pharmaceutically acceptable salts block alpha 1A-adrenergic receptors and are thus useful for the prevention of contractions of the prostate, urethra and lower urinary tract, without affecting blood pressure.
  [FR] Composés répondant à la formule générale (I), dans laquelle Y représente un groupe de liaison, choisi dans une large gamme, mais comprenant -COO-, -CH2COO-, -CONH-, -CON(CH3)-, -CH2CONH-, SO2NH-, -SO2N(CH3)- et -PO(OC2H5)NH-; W représente une chaîne alkylène; A représente un groupe phénylique substitué ou un groupe benzofurane ou benzodioxane; et R et R1 peuvent avoir plusieurs valeurs, mais R est de préférence un groupe volumineux. Ces composés et leurs promédicaments, énantiomères, diastéréoisomères, N-oxydes et leurs sels pharmaceutiquement acceptables bloquent les récepteurs alpha 1a-adrénergiques et sont de ce fait utilisables dans la prophylaxie des contractions de la prostate, de l'urètre et de la partie inférieure du tractus urinaire, et ce sans intervenir sur la tension artérielle.